Mountain View, Calif.– RenovoRx has announced the issuance of a new U.S. patent that expands protection for its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, a targeted approach to delivering chemotherapy directly to tumors via the company’s proprietary RenovoCath® device.
The newly issued patent (U.S. No. 12,290,564), titled “Methods for Treating Tumors,” strengthens RenovoRx’s growing intellectual property portfolio, which now includes 19 issued patents and 12 pending applications. The patent grants exclusive rights through November 2037 and covers methods of locally administering therapeutic agents to arteries or blood vessels near tumors after reducing the area’s microvasculature—a key technique to improve drug delivery precision and efficacy.
“This latest patent highlights the innovation behind our TAMP therapy platform and reinforces our competitive edge as we scale the commercialization of RenovoCath,” said Shaun Bagai, CEO of RenovoRx. “It represents our ninth U.S. patent and 19th globally, underlining the strategic strength of our intellectual property.”
RenovoCath, an FDA-cleared medical device, began generating commercial revenue in late 2024 as a stand-alone product. It also plays a central role in the company’s investigational drug-device combination being evaluated in the ongoing Phase III TIGeR-PaC clinical trial. That study is comparing intra-arterial administration of gemcitabine (via TAMP) to conventional systemic chemotherapy for the treatment of locally advanced pancreatic cancer.
“The expansion of our IP portfolio is not only crucial for commercialization but also supports the advancement of our late-stage clinical pipeline,” Bagai added.
RenovoRx’s TAMP platform is designed to improve therapeutic delivery to solid tumors while minimizing systemic exposure and side effects. As the company progresses with both commercial and clinical initiatives, the strengthened patent protection enhances its long-term positioning in the oncology space.
